AAV Purification

After the production of viral vectors, we also purify them in-house. With the increasing number of viral vector therapeutics entering clinical phases, their significance to the industry is growing. This success has amplified the demand for intensified manufacturing processes. However, AAV production remains challenging compared to more established platforms like monoclonal antibodies due to their structural complexity and limited technical repertoire.

Our downstream purification process encompasses the entire purification train, from the purification of plasmids to the capture and polishing of viral vectors, such as adeno-associated viruses (AAVs). In addition to conventional batch chromatography purification, we also employ various continuous twin-column chromatography techniques to purify our gene therapy products. By applying these modern chromatographic purification technologies, we aim to optimize the manufacturing of viral vector products early-on, demonstrating their potential to improve process productivity and product quality.